CD99 Matched Antibody Pair (241) (APMAB-241LY)

Siwy, J., Wendt, R., Albalat, A., He, T., Mischak, H., Mullen, W., ... & Beige, J. (2021). CD99 and polymeric immunoglobulin receptor peptides deregulation in critical COVID‐19: A potential link to molecular pathophysiology?. Proteomics, 21(20), 2100133.

Mattisson, J., Danielsson, M., Hammond, M., Davies, H., Gallant, C. J., Nordlund, J., ... & Forsberg, L. A. (2021). Leukocytes with chromosome Y loss have reduced abundance of the cell surface immunoprotein CD99. Scientific Reports, 11(1), 1-9.

Takheaw, N., Sittithumcharee, G., Kariya, R., Kasinrerk, W., & Okada, S. (2021). Anti-human CD99 antibody exerts potent antitumor effects in mantle cell lymphoma. Cancer Immunology, Immunotherapy, 70(6), 1557-1567.

Vaikari, V. P., Park, M., Keossayan, L., MacKay, J. A., & Alachkar, H. (2020). Anti-CD99 scFv-ELP nanoworms for the treatment of acute myeloid leukemia. Nanomedicine: Nanotechnology, Biology and Medicine, 29, 102236.

Wu, J., Zhang, L., Li, H., Wu, S., & Liu, Z. (2019). Nrf2 induced cisplatin resistance in ovarian cancer by promoting CD99 expression. Biochemical and biophysical research communications, 518(4), 698-705.

Cardoso, L. C., Soares, R. D. S., Laurentino, T. D. S., Lerario, A. M., Marie, S. K., & Oba-Shinjo, S. M. (2019). CD99 expression in glioblastoma molecular subtypes and role in migration and invasion. International journal of molecular sciences, 20(5), 1137.

Pasello, M., Manara, M. C., & Scotlandi, K. (2018). CD99 at the crossroads of physiology and pathology. Journal of cell communication and signaling, 12(1), 55-68.

Çelik, H., Sciandra, M., Flashner, B., Gelmez, E., Kayraklıoğlu, N., Allegakoen, D. V., ... & Üren, A. (2018). Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99. Oncogene, 37(16), 2181-2196.

Manara, M. C., Pasello, M., & Scotlandi, K. (2018). CD99: a cell surface protein with an oncojanus role in tumors. Genes, 9(3), 159.

Yeh, C. C., Chang, C. J., Twu, Y. C., Chu, C. C., Liu, B. S., Huang, J. T., ... & Yu, L. C. (2018). The molecular genetic background leading to the formation of the human erythroid-specific Xga/CD99 blood groups. Blood advances, 2(15), 1854-1864.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols

Related Products

Mouse Anti-CD99 Recombinant Antibody (3A10)

Mouse Anti-CD99 Recombinant Antibody (CBYY-C1659)

Mouse Anti-CD99 Recombinant Antibody (CBFYC-1503)

Mouse Anti-CD99 Recombinant Antibody (CBFYC-1502)

Mouse Anti-CD99 Recombinant Antibody (CBYY-C1660)

Mouse Anti-CD99 Recombinant Antibody (CBYY-C0073)

Mouse Anti-CD99 Recombinant Antibody (CBFYC-1505)

Mouse Anti-CD99 Recombinant Antibody (CBFYC-1504)

Mouse Anti-CD99 Recombinant Antibody (CBYY-C1661)

Rabbit Anti-CD99 Recombinant Antibody (CBNH-033)

Isotype control